共 50 条
Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives
被引:272
|作者:
Zhang, Rui Xue
[1
]
Wong, Ho Lun
[2
]
Xue, Hui Yi
[2
]
Eoh, June Young
[2
]
Wu, Xiao Yu
[1
]
机构:
[1] Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 2S2, Canada
[2] Temple Univ, Sch Pharm, 3304 North Broad St, Philadelphia, PA 19140 USA
关键词:
Nanomedicine;
Synergistic drug combinations;
Cancer therapy;
Strategies;
Perspectives;
METASTATIC BREAST-CANCER;
OVERCOMING MULTIDRUG-RESISTANCE;
ANTI-SURVIVIN SIRNA;
CO-DELIVERY;
IN-VITRO;
POLYMERIC MICELLES;
ANTICANCER DRUGS;
SOLID TUMORS;
MITOMYCIN-C;
NANOPARTICLE FORMULATION;
D O I:
10.1016/j.jconrel.2016.06.012
中图分类号:
O6 [化学];
学科分类号:
0703 ;
摘要:
Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:489 / 503
页数:15
相关论文